2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 334

Selective iNOS Inhibition Increases the Lymphatic Pulse and Drainage From Arthritic Joints in TNF-Tg Mice
Abstract Number: 2489

Selective JAK1 Inhibition in the Treatment of Rheumatoid Arthritis: Proof of Concept with GLPG0634
Abstract Number: 1225

Self Reported Comorbidity Is Common in Early Inflammatory Arthritis and Associated with Poorer Function and Quality of Life and Greater Disease Activity: Results From the Canadian Early Arthritis Cohort
Abstract Number: 946

Self-Reported Disease Activity and Health-Related Quality of Life in a Longitudinal Cohort of Patients with Systemic Lupus Erythematosus
Abstract Number: 1746

Semaphorin 3A Increases the Regulatory Characteristics of B-Regulatory Cells
Abstract Number: 1028

Semi-Quantitative Assessment of Bone Marrow Edema and Synovitis-Effusion in Osteoarthritis with the Knee Inflammation MRI Scoring System: A Target Lesion Based Methodology
Abstract Number: 2312

Senescent T Cells Promote Bone Loss in Rheumatoid Arthritis
Abstract Number: 107

Sensitivity to Change of the Ultrasound synovitis SONAR Score in RA Patients : Results of the Scqm Cohort
Abstract Number: 657

Serial Screening Shows That 28% of Systemic Lupus Erythematosus Adult Patients Carry an Underlying Primary Immunodeficiency
Abstract Number: 467

Seropositive Rheumatoid Arthritis Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors Achieve Improved Clinical Effectiveness After Switching to Rituximab Versus Switching to an Alternative Tumor Necrosis Factor Inhibitor
Abstract Number: 2465

Seroresponse Rates After Influenza Vaccination in Rheumatoid Arthritis Patients Treated with Biological Agents During the 2011–2012 Flu Season
Abstract Number: 2014

Serum 25(OH)D Levels in Adolescents and Young Adults with Juvenile Idiopathic Arthritis and Juvenile Onset Systemic Lupus Erythematosus: Prevalence and Association with Disease Activity
Abstract Number: 43

Serum Amyloid A Level in Knee Osteoarthritis: Systemic and/or Local Production and Pro-Inflammatory Properties On Human Chondrocytes and Fibroblast-Like Synoviocytes
Abstract Number: 1532

Serum Angiopoietin-2 Level Reflects the Disease Activity and Renal Function in Antineutrophilic Cytoplasmic Antibody-Associated Vasculitis
Abstract Number: 669

Serum Anti N-Methyl-D-Aspartate Receptor Subunit 1 Antibodies Are Elevated in SLE

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].